Quantcast
Ocugen says Indian partner’s vaccine 93.4% effective against severe COVID-19 – Metro US

Ocugen says Indian partner’s vaccine 93.4% effective against severe COVID-19

FILE PHOTO: COVID-19 vaccination in New Delhi
FILE PHOTO: COVID-19 vaccination in New Delhi

(Reuters) – The COVID-19 vaccine developed by Ocugen Inc’s Indian partner, Bharat Biotech, has been found to be 93.4% effective against severe cases of COVID-19 in a late-stage trial, the U.S. drug developer said on Friday.

(Reporting by Dania Nadeem in Bengaluru; Editing by Ramakrishnan M.)

More from our Sister Sites